Home News Rivaroxaban Safe, Effective in Renal Disease back to News
minute read
In PAD patients with chronic kidney disease who’ve undergone revascularization, rivaroxaban (Xarelto; Bayer/Janssen) can safely reduce major CV and limb events, new findings from the VOYAGER PAD trial suggest.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
